Testing of a sclerosing and embolizing gel for venous disease

静脉曲张是慢性静脉疾病表现谱的一部分， 其特征在于在功能不全的静脉中发生血液回流，导致静脉扩张。 下肢静脉曲张是由于大隐静脉瓣膜功能不全所致 （GSV）。除了美学问题，水肿和疼痛，静脉曲张可导致严重的 腿部溃疡等并发症。最近估计的静脉曲张的患病率， 在美国，男性为15%，女性为28%。静脉曲张的症状有哪些 在性腺静脉中观察到，引起女性严重腹痛和睾丸疼痛， 男性不育症胃食管静脉曲张常见于肝硬化患者， 门静脉高压导致危及生命的出血。 静脉曲张的治疗方法有哪些？机械技术，例如 使用结扎、剥离、用机械装置闭塞来防止回流， 使用硬化剂进行化学消融或使用激光或射频探针进行热消融 破坏血管壁这些疗法经常联合使用， 可能是次优的，导致症状复发和重做手术， 成本增加和生活质量恶化。 我们在CRCHUM开发了一种硬化和栓塞凝胶并获得专利， 壳聚糖是一种生物可吸收的凝胶，与硬化剂（十四烷基硫酸钠）结合。 这种凝胶在X射线和超声波下也是可见的，这允许在成像下安全输送 指导 该凝胶被授权给Cook Medical（美国），一家开发 用于介入放射学的医疗器械。我们建议与Cook Medical合作， Chitolytic是一家加拿大公司，供应药用级壳聚糖， 特别适用于静脉硬化疗法的制剂，并在猪静脉中进行测试 模型

Varicose veins are a part of a spectrum of manifestations of chronic vein disorders that are characterized by the occurence of blood reflux in incompetent veins leading to vein dilatation. Varicose veins are often observed in lower legs due valve failure of the great saphenous vein (GSV). Beside aesthetic concern, edema and pain, varicosities can lead to serious complications such as leg ulcers. The recent estimates of the prevalence of varicosities in the United States range from 15% among men to 28% in women. Varicose veins are also observed in gonadal veins causing severe abdominal pain in women and testicular pain and infertility in men. Gastro-esophageal varices veins are often observed in cirrhosis patient with portal hypertension leading to life threatening bleeding. Different techniques were proposed to treat varicose veins. Mechanical techniques such as ligation, stripping, occlusion with mechanical devices are used to prevent reflux whereas chemical ablation with sclerosant or thermal ablation with laser or radiofrequency probes aim to destroy the wall of the vein. These therapies are often used in combination and the results can be suboptimal leading to recurrence of symptoms and redo procedures leading to increase cost and deterioration of the quality of life. We have developed and patented a sclerosing and embolizing gel at CRCHUM made of chitosan a bio-absorbable gel combined with a sclerosant agent (Sodium Tetradecyl Sulfate). This gel is also visible under X-ray and ultrasound which allows safe delivery under imaging guidance. The gel was licensed to Cook Medical (USA), a world leader company in the development of medical device for interventional radiology. We propose in partnership with Cook Medical and Chitolytic, a canadian company supplying pharmaceutical grade chitosan, to develop a formulation specifically adapted for venous sclerotherapy and test it in a porcine venous model.